Purdue and Exicure partner on psoriasis in deal worth up to $790 million

13 December 2016

Privately-held US firms Purdue Pharma and Exicure have announced a new research collaboration and license agreement aimed at discovering and developing a treatment for psoriasis in a deal that could eventually be worth up to $790 million plus royalties on successful products.

The agreement will also target treatments for other diseases that could be treated with a gene regulation approach using Exicure’s Spherical Nucleic Acid (SNA) technology.

This deal sees Purdue gain full worldwide development and commercial rights to the topical plaque psoriasis drug AST-005, and also rights to three additional collaboration targets. Data from a recently-completed Phase I trial of AST-005 showed the drug to be safe and tolerable in 15 patients.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK